These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30817619)

  • 1. TCM therapies combined with chemotherapy for preventing recurrence and metastasis in postoperative II to IIIA NSCLC: A protocol for a systematic review and meta-analysis.
    Chen S; Zhang Z; Zhang X; Qi R; Jiang J; Zhang X; Xi Y; Liu R; Guo Q; Zheng H; Hua B
    Medicine (Baltimore); 2019 Mar; 98(9):e14724. PubMed ID: 30817619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of TCM therapies combined with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of gastric cancer: A protocol for systematic review and meta-analysis.
    Zhu X; Wu Z; Cao Y; Gao R; Zhang X; Li J
    Medicine (Baltimore); 2021 Jan; 100(4):e24337. PubMed ID: 33530226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
    Chen H; Yao X; Liu Z; Li T; Xu C; Wang J; Sui X; Leung EL; Wu Q
    Medicine (Baltimore); 2019 Sep; 98(39):e17350. PubMed ID: 31574877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of traditional Chinese medicine combined with chemotherapy on immune function and quality of life in patients with non-small cell lung cancer: A protocol for systematic review and meta-analysis.
    Zhao LN; Yang YQ; Wang WW; Li Q; Xiao H
    Medicine (Baltimore); 2020 Nov; 99(45):e22859. PubMed ID: 33157928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Traditional Chinese Medicine Treatment as Adjuvant Therapy in Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer: Study Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Jiang Y; Liu LS; Shen LP; Liu JX; Jiang GN; Gu AQ; Li HC; Li Q; Li HG; Huang PX
    Clin Lung Cancer; 2019 Sep; 20(5):e541-e547. PubMed ID: 31230892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor.
    Créquit P; Trinquart L; Ravaud P
    BMJ Open; 2016 Aug; 6(8):e011841. PubMed ID: 27489157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.
    Yao J; Jiao L; Yao Y; Lu Y; Shi J; Li J; Chen P; Xu L; Gong Y
    Trials; 2020 Apr; 21(1):309. PubMed ID: 32245480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
    Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
    Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
    Tsuchiya T; Matsumoto K; Miyazaki T; Doi R; Tokunaga S; Yamaguchi H; Tomoshige K; Watanabe H; Nagayasu T; Sugio K
    BMC Cancer; 2021 Mar; 21(1):249. PubMed ID: 33685421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined modality therapy of non-small cell lung cancers.
    Juretic A; Sobat H; Samija M
    Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chinese patent medicine Fei-Liu-Ping ointment as an adjunctive treatment for non-small cell lung cancer: protocol for a systematic review.
    Zheng H; He S; Liu R; Xu X; Xu T; Chen S; Guo Q; Gao Y; Hua B
    BMJ Open; 2017 Jan; 7(1):e015045. PubMed ID: 28093444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum versus immunotherapy for early resectable non-small cell lung cancer: A protocol for systematic review and meta analysis.
    Tong Z; Luo F; Yang X; Kang M; Lin J
    Medicine (Baltimore); 2020 Oct; 99(43):e22349. PubMed ID: 33120735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial.
    Shen WY; Ji J; Zuo YS; Pu J; Xu YM; Zong CD; Tao GZ; Chen XF; Ji FZ; Zhou XL; Han JH; Wang CS; Yi JG; Su XL; Zhu WG
    Radiother Oncol; 2014 Jan; 110(1):120-5. PubMed ID: 24183868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy for surgically resected non-small cell lung cancer.
    Heon S; Johnson BE
    J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S39-42. PubMed ID: 22502967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study.
    Wang XQ; Zhang Y; Hou W; Wang YT; Zheng JB; Li J; Lin LZ; Jiang YL; Wang SY; Xie Y; Zhang HL; Shu QJ; Li P; Wang W; You JL; Li G; Liu J; Fan HT; Zhang MY; Lin HS
    Chin J Integr Med; 2019 Nov; 25(11):812-819. PubMed ID: 31471834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of TCM combined with chemotherapy for SCLC: a systematic review and meta-analysis.
    Chen S; Bao Y; Xu J; Zhang X; He S; Zhang Z; Qi R; Jiang J; Liu R; Guo Q; Zhang X; Xi Y; Zheng H; Hua B
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2913-2935. PubMed ID: 32797283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Postoperative adjuvant therapy in combined lung cancer treatment].
    Cicenas S; Piscikas DA; Jakubauskiene R
    Medicina (Kaunas); 2004; 40 Suppl 1():156-60. PubMed ID: 15079128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of traditional Chinese Medicine combined with chemotherapy in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized clinical trials.
    Yang J; Zhu X; Yuan P; Liu J; Wang B; Wang G
    Support Care Cancer; 2020 Aug; 28(8):3571-3579. PubMed ID: 32266566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.